Loading
Bladder and Urothelial Cancer Treatments · Journal article
Journal of Cancer Research and Clinical Oncology · August 11, 2026
Encouraging direction, but not yet definitive.
This is a retrospective single-center case series of 21 BCG-unresponsive pT1 NMIBC patients treated with OncoTherad nanoimmunotherapy, with exploratory biomarker profiling and in vitro mechanistic work. The study reports favorable clinical outcomes and candidate biomarkers (HER-2, SERBP1, HABP4, IFN-γ) associated with recurrence and disease control, but lacks prospective validation, control comparison, and adequate sample size to establish clinical utility.
Retrospective observational cohort study with translational biomarker profiling. Patients with BCG-unresponsive pT1 non-muscle invasive bladder cancer treated with OncoTherad nanoimmunotherapy; setting and center not specified beyond single institution implied by cohort structure. Intervention: OncoTherad (MRB-CFI-1) nanoimmunotherapy. n = 21.
OncoTherad achieved a pathological complete response rate of 71.4% Mean recurrence-free survival of 21.2 months with progression rate of 4.8% HER-2 and SERBP1 expression significantly associated with recurrence and reduced recurrence-free survival
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The reported biomarkers (HER-2, SERBP1, HABP4, IFN-γ) are positioned as candidates for identifying patients likely to benefit from or recur after OncoTherad therapy, but require prospective multicenter validation before clinical application. Clinicians should consider this exploratory evidence only as hypothesis-generating pending larger studies.
Single-center retrospective cohort of 21 patients with identified biomarkers and clinical outcomes, but lacking prospective validation, control group, and adequate power to establish causality or guide practice.
As stated by the source record.
Quoted from the source exactly as published.
The reported biomarkers (HER-2, SERBP1, HABP4, IFN-γ) are positioned as candidates for identifying patients likely to benefit from or recur after OncoTherad therapy, but require prospective multicenter validation before clinical application. Clinicians should consider this exploratory evidence only as hypothesis-generating pending larger studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
To evaluate the clinical and translational effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy and to investigate biomarkers associated with therapeutic response in patients with Bacillus Calmette-Guérin (BCG)-unresponsive pT1 non-muscle invasive bladder cancer (NMIBC). A retrospective observational cohort of 21 patients with BCG-unresponsive pT1 NMIBC treated with OncoTherad was analyzed. Tumor samples obtained before and after treatment were evaluated according to clinical outcome. Immunohistochemistry was performed to quantify human epidermal growth factor receptor 2 (HER-2), SERPINE1 mRNA-binding protein 1 (SERBP1), hyaluronic acid-binding protein 4 (HABP4), and IFN- γ expression. In parallel, high-content image-based phenotypic profiling was performed in 5637 urothelial carcinoma cells to investigate treatment-associated cellular remodeling. OncoTherad achieved a pathological complete response rate of 71.4%, with a mean recurrence-free survival of 21.2 months and a low progression rate of 4.8%. HER-2 and SERBP1 expression were significantly associated with recurrence and reduced recurrence-free survival, whereas increased HABP4 and IFN- γ expression correlated with sustained disease control. Phenotypic profiling demonstrated reproducible alterations in nuclear architecture and vesicular organization, supporting coordinated cellular reprogramming associated with innate immune activation. Histopathological analyses additionally demonstrated tumor downstaging in recurrent cases, suggesting attenuation of tumor aggressiveness after therapy. Collectively, the integration of clinical outcomes, tissue biomarker profiling, and machine learning-based phenotypic analyses provides a framework supporting biomarker-oriented bladder-preserving immunotherapy in refractory NMIBC. OncoTherad demonstrated promising immunomodulatory and antitumor activity in BCG-unresponsive pT1 NMIBC. HER-2, SERBP1, HABP4, and IFN- γ emerged as candidate biomarkers associated with therapeutic response and clinical outcome, supporting further prospective validation in larger multicenter studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.